Blue Bird Corporation remains a “Strong Buy” due to its solid backlog, strong funding, and undervaluation, despite recent stock price underperformance. Read more here.

Analysts at StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE – Get Free Report) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biotechnology ...

Blue Bird Corporation is a compelling investment due to its focus on electric school buses and attractive stock valuation despite recent performance setbacks. Read more here.

(NASDAQ:BLUE – Get Free Report) had its target price dropped by analysts at Wells Fargo & Company from $40.00 to $5.00 in a ...

Blue Bird (BLBD) came out with quarterly earnings ... the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on ...

Francis Creek Sportsman’s Club will host its 23rd annual “Show Off Your Buck Contest” March 1 at its clubhouse on the corner ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Latest chapter in partnership between leading telco and low Earth orbit satellite provider sees firms unveil new organisation ...

The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the ...

Patsy headed to Hollywood again in 1989 for her role in Lethal Weapon 2, starring Mel Gibson and Danny Glover. She played ...

While weather in the mountains is never a guarantee, visiting these ski resorts will increase your chances of scoring ...

AST SpaceMobile (AST) and Vodafone used the Mobile World Congress in Barcelona, as well as AST’s financial results, to ...